CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 30 enrolled
Drug / intervention
BioSpy Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06380361
NCT06380361N/ACompleted

InvestigatioN of a Smart Probe for Lung lEsion Characterization Using Impedance Technology

Sensome·interventional·Posted Apr 23, 2024·Updated Apr 21, 2026

In Brief

A clinical study evaluating BioSpy System for Lung Cancer. Completed, enrolled 30 participants across 2 sites in 2 countries.

Detailed Summary

The objective of the study is to evaluate the feasibility of the BioSpy System sensor to differentiate tissues that are encountered during bronchoscopic biopsy of endobronchial tumors and peripheral lung nodules and masses.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesAustralia, France
Collaborators--

Timeline

N/ACompletedFinished
20252026
First PostedApr 23, 2024
Enrollment StartMar 28, 2024
Primary CompletionApr 23, 2025
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 2.2 years ago

Interventions

BioSpy Systemdevice

One arm only - in all eligible study patients, the study device will be used. In patients with suspicion of lung cancer a bronchoscope will be inserted to navigate to the lesion where a biopsy sample will be taken for histology analysis. In the current trial, the device will be used to perform electrophysiological measurements in the lesion during bronchoscopic biopsy procedure.